Cardiff Oncology (NASDAQ:CRDF) Stock Price Expected to Rise, HC Wainwright Analyst Says

Cardiff Oncology (NASDAQ:CRDF) had its price target upped by research analysts at HC Wainwright from $13.00 to $17.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 300.94% from the company’s previous close.

Separately, Piper Sandler increased their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $4.24 on Friday. The stock has a market capitalization of $216.81 million, a PE ratio of -4.51 and a beta of 1.77. Cardiff Oncology has a 1-year low of $2.01 and a 1-year high of $6.42. The business has a 50-day moving average of $4.06 and a 200 day moving average of $3.24.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was acquired at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the acquisition, the director now owns 1,047,876 shares in the company, valued at $2,724,477.60. This represents a 50.18 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in Cardiff Oncology in the 4th quarter worth approximately $25,000. ProShare Advisors LLC bought a new stake in shares of Cardiff Oncology during the fourth quarter valued at approximately $50,000. Raymond James Financial Inc. bought a new stake in shares of Cardiff Oncology during the fourth quarter valued at approximately $56,000. Voya Investment Management LLC bought a new stake in shares of Cardiff Oncology during the fourth quarter valued at approximately $57,000. Finally, Caxton Corp bought a new stake in shares of Cardiff Oncology during the fourth quarter valued at approximately $58,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.